Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. (NYSE: RCUS) on October 1, 2020. The filing reports a material corporate governance event: the appointment of a new Chief Operating Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details.
Material Changes and Executive Appointment
On October 1, 2020, Jennifer Jarrett was appointed as Chief Operating Officer. Ms. Jarrett previously served as Arcus's Chief Operating and Financial Officer (2018-2019) and Chief Business Officer/CFO (2017-2018). She joins from Uber, where she was Vice President of Corporate Development and Capital Markets.
Compensation and Equity Arrangements
- Base Salary: $500,000 annually.
- Target Bonus: 50% of base salary.
- Stock Options: 900,000 shares granted under the 2020 Inducement Plan and 2018 Equity Incentive Plan. Exercise price equals fair market value on the first date of employment; vests monthly over four years.
- Restricted Stock Units (RSUs): 400,000 RSUs to be received upon the 2021 annual refresher awards; vests quarterly over four years.
- Severance: Standard agreements for change of control (cash severance, medical premiums, accelerated equity vesting) and termination without cause (cash severance, medical premiums, pro-rata bonus).
Outlook and Risks
The filing does not contain specific guidance, outlook, or risk factors beyond the standard terms of the executive employment agreement.
Key Facts for Investor Verification
- Confirmation of the total equity grant size (900,000 options + 400,000 future RSUs) relative to the company's outstanding share count.
- Verification of the exercise price for the 900,000 stock options based on the fair market value on Ms. Jarrett's start date.
- Review of the company's cash burn rate to assess the impact of the new $500,000 base salary and potential bonus obligations.
- Confirmation of Ms. Jarrett's current board seat status and any potential conflicts of interest with her roles at Arena Pharmaceuticals and Syndax Pharmaceuticals.